**DR Congo Rolls Out Ebola Vaccine for Health Workers as Death Toll Rises**
*Bunia, Ituri Province, Democratic Republic of the Congo – September 20, 2026*
In response to the escalating Ebola outbreak in the Democratic Republic of the Congo (DRC), health workers in the Ituri province have commenced receiving the Ervebo vaccine. This initiative, which began on September 19, 2026, is aimed at providing protection to those on the front lines of the epidemic, which has become the fastest-growing outbreak of Ebola in history.
The provincial governor, Major-General Gaby Kasongo Mulumba, emphasized the critical role of health workers in managing the outbreak, stating that they are "particularly exposed and deeply involved in the response." The vaccination campaign is supported by the World Health Organization (WHO) and Doctors Without Borders (MSF), and it will also extend to North Kivu province, where cases have been surging.
Approximately 50,000 health and frontline workers are slated to receive the Ervebo vaccine, which is primarily designed to combat the Zaire strain of the Ebola virus. However, the current outbreak is attributed to the Bundibugyo strain, and its effectiveness against this variant will be closely monitored in 20,000 recipients over the next year. There are ongoing clinical trials aimed at developing a licensed vaccine specifically for the Bundibugyo strain, as no proven treatment or licensed vaccine currently exists for this outbreak.
Steve Ahuka, a Congolese official involved in the health task force addressing the Ebola crisis, acknowledged the uncertainty surrounding the vaccine's effectiveness against the Bundibugyo strain. "We don’t know to what degree it might be effective against the Bundibugyo strain," he stated.
Dr. Jeannot Elua, a healthcare worker in Bunia, expressed his commitment to receiving the vaccine, highlighting the lack of choice for those in the profession. "We healthcare workers don’t really have a choice. We are going to receive it," he noted, adding that some individuals had previously received the earlier vaccine, which was mandatory.
The WHO has reported that the outbreak has resulted in at least 3,639 deaths and approximately 7,541 infections since May 2026, with 1,823 recoveries recorded. The organization also announced in August that 70,000 doses of the Ervebo vaccine had been approved for use in the DRC under a compassionate-use program. This program allows for the use of medical products in serious disease situations, even if they have not been specifically approved for those uses.
While WHO officials have pointed to "encouraging signs" that the transmission of the virus may be slowing, MSF has cautioned that there is no definitive evidence indicating that the epidemic is under control. The situation remains critical as aid agencies intensify their efforts to contain the outbreak, particularly in the most affected regions.
As the vaccination campaign unfolds, health authorities are hopeful that the Ervebo vaccine will provide essential protection to healthcare workers, who are at the forefront of the battle against Ebola. The ongoing monitoring of vaccine efficacy will be crucial in informing future public health strategies and interventions in the DRC.